HRAS and neoplasm: In terms of cell signaling and gene regulation, aberrant activation of signaling pathways (notably FGFR3 mutations or fusions, HRAS overexpression, and alterations in MAPK components such as MAP4K3) further promotes tumor growth and progression [26].